MRC1 and colorectal carcinoma: Importantly, similar success has been replicated in MSI-high CRC [29] and across multiple other cancer types [30], leading to pembrolizumab being granted FDA approval for use in unresectable or metastatic MMR-deficient or MSI-high solid tumors.